colorectal cancer
gynecologic cancer

PMS2-Associated Lynch Syndrome and Cancer Risks

In a study reported in the Journal of Clinical Oncology, ten Broeke et al found that patients with Lynch syndrome associated with PMS2 mutation are at increased risk of colorectal and endometrial cancers but not other cancers associated with the syndrome. As noted by the investigators, Lynch...

Gastrointestinal Cancer
Colorectal Cancer

Ipilimumab in Combination With Nivolumab for MSI-H or dMMR Metastatic Colorectal Cancer

On July 10, 2018, ipilimumab (Yervoy) was granted accelerated approval for use in combination with nivolumab (Opdivo) for the treatment of patients at least 12 years of age with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer progressing...

Colorectal Cancer

ERBB2/ERBB3-Mutant Colorectal Cancer

A study reported in the Journal of the National Cancer Institute by Loree and colleagues found that ERBB2/ERBB3 mutations in colorectal cancer are associated with microsatellite instability and PIK3CA mutation. Kanwal Raghav, MD, MBBS, of the Division of Gastrointestinal Medical Oncology, The...

colorectal cancer
immunotherapy

FDA Grants Breakthrough Therapy Designation for Encorafenib Plus Binimetinib and Cetuximab in BRAF V600E–Mutant Metastatic Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for encorafenib (Braftovi) in combination with binimetinib (Mektovi) and cetuximab (Erbitux) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC), as detected by...

Colorectal Cancer
Survivorship

ACS Nutrition and Physical Activity Guidelines for Cancer Survivors and Outcomes After Colon Cancer Diagnosis

IN A STUDY reported in JAMA Oncology, Erin L. Van Blarigan, ScD, of the University of California, San Francisco, and colleagues found that adherence to American Cancer Society (ACS) nutrition and physical activity guidelines for cancer survivors was associated with improved survival among patients ...

Colorectal Cancer

BRAF Mutations, Survival, and Recurrence in Patients With Colorectal Cancer Liver Metastases

In a study reported in JAMA Surgery by Margonis and colleagues, the presence of a BRAF V600E mutation was associated with a higher risk of recurrence and poorer overall survival among patients undergoing surgical resection of liver metastases from colorectal cancer. Matthew J. Weiss, MD, of the...

breast cancer
colorectal cancer
prostate cancer

Following a Healthy Diet and Avoiding Alcohol May Reduce Overall Cancer Risk

The World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) has estimated that in developed countries, about 35% of breast cancers and 45% of colorectal cancers could be prevented with a better adherence to nutritional recommendations. A large prospective study evaluating...

colorectal cancer
kidney cancer
hepatobiliary cancer
lung cancer
pancreatic cancer
issues in oncology
bladder cancer

Large Disparities in Cancer Mortality Rates Found Among Different Racial/Ethnic Populations in New York State

According to the American Cancer Society, cancer is the leading cause of death for Hispanics and Asian/Pacific Islanders in the United States. However, their cancer burden is less than that of non-Hispanic whites and especially non-Hispanic blacks, who bear the most disproportionate share of the...

Colorectal Cancer
Immunotherapy

Nivolumab Plus Low-Dose Ipilimumab Approved for Second-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

On July 11, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric patients aged 12 years and older with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal...

palliative care
colorectal cancer
lung cancer
cost of care

Geographic Differences in End-of-Life Cancer Care

When it comes to how much end-of-life care a patient with cancer receives, geography may, indeed, be destiny, according to new research led by Harvard Medical School that found differences in this type of cancer care across different parts of the country. The findings, published by Keating et al...

colorectal cancer
immunotherapy

FDA Approves Nivolumab Plus Low-Dose Ipilimumab for Second-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

Today, the U.S. Food and Drug Administration (FDA) approved  nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) for the treatment of adult and pediatric patients aged 12 years and older with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR)...

colorectal cancer
survivorship

Dietary Insulin Load and Risk of Disease Recurrence in Stage III Colon Cancer

New research led by Dana-Farber Cancer Institute investigators suggests that patients treated for nonmetastatic colon cancer may sharply reduce the risk that the disease will return by following a diet low in carbohydrates and other foods that raise insulin levels. In a study published by...

colorectal cancer
cost of care

AMA Plans Advocacy Outreach to Expand Colorectal Screening

Building on the efficacy of colorectal cancer screening, the American Medical Association (AMA) endorsed a plan at its Annual Meeting to work with physicians and payers to make the screening more available and affordable. Challenges with insurance coverage remain a barrier to colorectal cancer...

Solid Tumors
Gastrointestinal Cancer
Colorectal Cancer

Care for Colorectal Cancer Costs Twice as Much in Western Washington vs British Columbia, With Similar Survival

It is widely acknowledged that the costs of cancer care are much higher in the United States than in Canada, with outcomes that are thought to be similar. A new study presented at the 2018 ASCO Annual Meeting supports that view, by documenting and quantifying the differences in health-care costs...

Solid Tumors
Gastrointestinal Cancer
Colorectal Cancer

Less Is More: No Benefit Reported for Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer

With a growing emphasis on value in cancer care, some types of resource-intensive therapies may need to be reconsidered. One such treatment may be hyperthermic intraperitoneal chemotherapy, which showed no benefit during surgery for colorectal cancer confined to the peritoneum in the PRODIGE 7...

Solid Tumors
Colorectal Cancer

Following Guidelines for Healthy Eating and Physical Activity May Improve Survival in Patients Treated for Colon Cancer

Following guidelines for proper nutrition, maintaining a healthy weight, and staying physically active may improve survival among patients treated for colon cancer, according to the results of a study with nearly 1,000 patients followed for a median of 7 years.1 “The study suggests that if...

colorectal cancer

Howard S. Hochster, MD, on Colorectal Cancer: Results From the E7208 Trial

Howard S. Hochster, MD, of Rutgers-Cancer Institute of New Jersey, discusses study findings on irinotecan and cetuximab vs irinotecan, cetuximab, and ramucirumab as second-line therapy of advanced colorectal cancer following oxaliplatin and bevacizumab-based therapy (Abstract 3504).

colorectal cancer

Michael J. Overman, MD, and François Quenet, MD, on Colorectal Cancer: Results From the PRODIGE 7 Trial

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and François Quenet, MD, of the Institut Régional du Cancer de Montpellier, discuss phase III study findings on hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis (Abstract LBA3503).

colorectal cancer
solid tumors
gynecologic cancer

2018 ASCO: Genomic Study Finds Lynch Syndrome Is Common Among Patients With MSI-High Tumors

A genomic study of more than 15,000 tumor samples showed that people who have tumors with high microsatellite instability (MSI-H)—a genomic marker associated with a large number of genetic mutations in the tumor—are more likely to have Lynch syndrome, a hereditary condition that...

Colorectal Cancer

Risk of Recurrence in Stage III Colon Cancer According to RAS- and BRAF-Mutation Status

In a study in the PETACC-8 trial population reported in JAMA Oncology, Julien Taieb, MD, PhD, of the Université Paris Descartes, and colleagues found that the risk of recurrence in patients with stage III colon cancer differed for the primary tumor location according to RAS- and BRAF-mutation...

Colorectal Cancer
Breast Cancer
Hepatobiliary Cancer
Lung Cancer
Kidney Cancer
Prostate Cancer
CNS Cancers
Leukemia

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2018 Guidelines Updates

In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) covering 8 tumor types. Guidelines are now published for more than 60 tumor types and topics. Some of the key updates were presented at NCCN’s 23rd...

Solid Tumors
Colorectal Cancer

Nut Consumption in Patients With Stage III Colon Cancer

People with stage III colon cancer who regularly eat tree nuts are at significantly lower risk of cancer recurrence and mortality than those who don’t, according to findings published by Fadelu et al in the Journal of Clinical Oncology.1 Study Findings The study followed 826 participants in the...

Breast Cancer
Colorectal Cancer
Survivorship

Expert Point of View: Timothy Gilligan, MD, MSc

“IN THE PAST, patients were often told to rest and reduce their physical activity during treatment, but we now know that exercise is both safe and beneficial,” said Timothy Gilligan, MD, MSc, moderator of a presscast where these results were presented prior to the Cancer Survivorship Symposium....

Breast Cancer
Colorectal Cancer
Survivorship

Four Years Posttreatment, Exercise Improves Physical Activity Levels, Reduces Fatigue in Patients With Breast and Colon Cancers

IN PATIENTS WITH breast and colon cancers, a physical exercise intervention conducted during adjuvant chemotherapy improved total physical activity levels 4 years after treatment, with a trend toward less fatigue, according to a follow-up study from the randomized multicenter PACT study, presented...

colorectal cancer
immunotherapy

FDA Accepts sBLA for Nivolumab Plus Ipilimumab in Previously Treated MSI-H or dMMR Metastatic Colorectal Cancer

On March 27, the U.S. Food and Drug Administration (FDA) accepted a supplemental biologics license application (sBLA) for nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the treatment of adults with microsatellite instability–high (MSI-H) or mismatch repair deficient...

Colorectal Cancer

Duration of Adjuvant Oxaliplatin-Based Therapy for Stage III Colon Cancer

“At Microphone 1” is an occasional column written by Steven E. Vogl, MD, of the Bronx, New York. When he is not in his clinic, he can generally be found at major oncology meetings and often at the microphone, where he stands ready with critical questions for presenters of new data. The opinions...

Colorectal Cancer
Survivorship

Long-Term Risk of Cardiovascular Disease Increased Among Colorectal Cancer Survivors

COMPARED TO the general population, the risk of cardiovascular disease among colorectal cancer survivors was significantly increased more than 10 years after their cancer diagnosis, according to research presented by David Baraghoshi, MSTAT candidate, of the Huntsman Cancer Institute at the...

colorectal cancer

Alan P. Venook, MD, on Selecting Treatment for Advanced Colorectal Cancer

Alan P. Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses which biomarkers to order and when, the role of checkpoint inhibitors, and chemotherapy choices.

Solid Tumors
Colorectal Cancer
Supportive Care
Pain Management
Palliative Care
Survivorship
Issues in Oncology

Support, Inform Patients With ASCO Resources

Stock your practice with ASCO resources for your patients. Visit ASCO’s patient information website, Cancer.Net, for a newly updated comprehensive guide to colorectal cancer at cancer.net/colorectal and a shorter, one-page colorectal cancer fact sheet. Copies can be purchased from the ASCO...

Colorectal Cancer
Gastrointestinal Cancer
Immunotherapy

Triplet Therapy Poses a Triple Threat to BRAF-Mutated Colorectal Cancers

Triplet therapy that inhibits the BRAF, MEK, and epidermal growth factor receptor (EGFR) pathways appears promising in BRAF-mutated colorectal cancer, a malignancy that typically does not respond to BRAF inhibition alone. Early results from the BEACON CRC study showed a 48% response rate and an...

Gastrointestinal Cancer
Colorectal Cancer

Studies Explore Colon Tumor Sidedness, Lung Radiation Dose in Esophageal Cancer, Pembrolizumab in Liver Cancer, and More

Along with full coverage of key presentations from the 2018 Gastrointestinal Cancers Symposium, The ASCO Post brings our readers this additional news roundup.  Side Matters in Colon Cancer One of the studies included in the global IDEA trial, which compared 3 vs 6 months of adjuvant chemotherapy in ...

Colorectal Cancer

EXPERT POINT OF VIEW: Wafik S. El-Deiry, MD, PhD, FACP

WAFIK S. EL-DEIRY, MD, PhD, FACP, Deputy Cancer Center Director for Translational Research, and Co-Leader of the Molecular Therapeutics Program at Fox Chase Cancer Center, Philadelphia, shared his thoughts on these findings with The ASCO Post. In essence, Dr. El-Deiry suggested the comparison does ...

Colorectal Cancer

Small Study Evaluates Treatment Sequencing in Patients With Metastatic Colorectal Cancer

THE OPTIMAL treatment sequence for two approved agents in metastatic colorectal cancer may be regorafenib (Stivarga) before cetuximab (Erbitux), according to results from the small randomized Japanese REVERCE trial presented at the 2018 Gastrointestinal Cancers Symposium.1 Giving regorafenib...

Colorectal Cancer

Investigational Genomic Tool Identifies Consensus Molecular Subtype of Colon Tumor and May Predict Risk of Recurrence

AN INVESTIGATIONAL TOOL called ColotypeR classifies colon cancers by molecular subtype and creates a subtype-specific risk of recurrence, according to research. Developers of the tool say it will be able to guide treatment decisions. Colon cancer is highly heterogeneous in prognosis and response to ...

colorectal cancer
survivorship
symptom management

David Baraghoshi, on Colorectal Cancer and Cardiovascular Disease Risk

David Baraghoshi, of the Huntsman Cancer Institute at the University of Utah, discusses an assessment of cardiovascular risk more than 10 years after diagnosis for colorectal cancer survivors compared with a cancer-free general population cohort (Abstract 113).

Solid Tumors
Colorectal Cancer

Use of Circulating Tumor Cells to Detect Colorectal Cancer and Adenomas

Circulating tumor cells (CTCs) in the blood had an accuracy of up to 88% in detecting colorectal cancer and 84% in identifying adenomas, in a study from Taiwan presented at the 2018 Gastrointestinal Cancers Symposium by Wen-Sy Tsai, MD, of Linkou Chang Gung Memorial Hospital in Taipei.1 “The study ...

colorectal cancer
immunotherapy

Combination Immunotherapy in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

As reported in the Journal of Clinical Oncology by Overman et al, findings in the nivolumab (Opdivo) plus ipilimumab (Yervoy) cohort of the CheckMate-142 study indicate a high response rate and durable responses with the combination in previously treated patients with DNA mismatch...

breast cancer
colorectal cancer
survivorship

2018 SURVIVORSHIP: Exercising During Chemotherapy for Breast or Colon Cancer Has Long-Term Benefits

A follow-up study to a randomized clinical trial reveals that exercising during adjuvant chemotherapy helps people engage in more physical activity years later. Four years later, people with breast or colon cancer who had participated in an 18-week exercise program while receiving chemotherapy...

Colorectal Cancer

EXPERT POINT OF VIEW: Zsofia Kinga Stadler, MD

DISCUSSANT ZSOFIA KINGA STADLER, MD, of Memorial Sloan Kettering Cancer Center, found the nivolumab (Opdivo)/ipilimumab (Yervoy) combination results very encouraging but was also impressed with the monotherapy arm. Both approaches are significant advances in treatment, she said.  “The treatment of ...

Colorectal Cancer
Immunotherapy

Nivolumab Plus Ipilimumab Improves Outcomes in Metastatic Colorectal Cancer

IN THE FIRST REPORT of the full cohort of CheckMate-142, nivolumab (Opdivo) plus ipilimumab (Yervoy) led to a 1-year overall survival rate of 85% in previously treated patients with metastatic colorectal cancer who have DNA mismatch repair–deficient (dMMR) or microsatellite instability–high...

colorectal cancer
immunotherapy

Is There a Benefit of Maintenance Bevacizumab During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer?

As reported by Aparicio et al in the Journal of Clinical Oncology, a French phase III trial (PRODIGE 9) showed no benefit of maintenance bevacizumab (Avastin) during postinduction chemotherapy-free intervals in metastatic colorectal cancer. Study Details In the open-label trial, 491 patients from ...

breast cancer
colorectal cancer

Two Genetic Mutations Implicated in Breast Cancer Emerge From Study of Lynch Syndrome

Researchers at Columbia University Irving Medical Center (CUIMC) and GeneDx, a genetic testing company, have identified two new genetic mutations associated with breast cancer: MSH6 and PMS2. The researchers’ study—published by Roberts et al in Genetics in Medicine—suggests that...

breast cancer
colorectal cancer
gynecologic cancer
hepatobiliary cancer
lung cancer
pancreatic cancer
gastroesophageal cancer

Detecting and Localizing Eight Cancer Types With One Multianalyte Blood Test

Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and also helps identify the location of the cancer. The test, called CancerSEEK, is a unique noninvasive, multianalyte test that simultaneously evaluates levels of eight cancer...

colorectal cancer
immunotherapy

2018 GI CANCERS SYMPOSIUM: Nivolumab Plus Ipilimumab Yields Survival Benefit in Metastatic Colorectal Cancer

Nivolumab (Opdivo) plus ipilimumab (Yervoy) led to a 1-year overall survival rate of 85% in previously treated metastatic colorectal cancer patients with DNA mismatch repair–deficient (dMMR) or microsatellite instability–high (MSI-H) tumors. These data were presented in the first report ...

colorectal cancer

Mark Saunders, MD, PhD, on Colorectal Cancer: Results From the SCOT Trial

Mark Saunders, MD, PhD, of Christie Hospital, discusses study findings on tumor sidedness and the influence of chemotherapy duration on disease-free survival (Abstract 558).

colorectal cancer

Thierry André, MD, and Michael J. Overman, MD, on Colorectal Cancer: Results From Two CheckMate-142 Trials

Thierry André, MD, of Hôpital Saint-Antoine, and Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from their respective CheckMate-142 studies on nivolumab and ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer (Abstracts 553, 554).

breast cancer
colorectal cancer
lung cancer
skin cancer
issues in oncology

Growing Socioeconomic and Racial Disparities in Management of Brain Metastases

Increasing use of a potentially life-saving treatment for metastatic cancer is leaving too many vulnerable patients behind, according to a new study from Yale Cancer Center/Smilow Cancer Hospital published by Kann et al in JNCCN – Journal of the National Comprehensive Cancer Network. The...

Colorectal Cancer
Survivorship

Fiber Is Only One Component in Improving Outcomes in Cancer Survivors

SINCE 2003, every iteration of the American Cancer Society’s Nutrition Guidelines for Cancer Survivors has advocated for a plant-based diet with ample quantities of whole grains, as well as vegetables and fruits.1-3 This recommendation has been based primarily on data that such foods play in...

Colorectal Cancer

Outcomes Associated With Higher Fiber Intake After Colorectal Cancer Diagnosis

IN A STUDY reported in JAMA Oncology, Mingyang Song, MD, ScD, of Massachusetts General Hospital and Harvard Medical School, and colleagues found that higher fiber intake after diagnosis of nonmetastatic colorectal cancer is associated with improved colorectal cancer–specific and overall survival.1 ...

colorectal cancer

Combination Agent in Asian Patients With Previously Treated Metastatic Colorectal Cancer

In the Asian phase III TERRA trial, trifluridine/tipiracil (Lonsurf) produced a significant improvement in overall survival vs placebo among patients with metastatic colorectal cancer refractory or intolerant of standard chemotherapies with or without exposure to biologic therapies. These findings...

Advertisement

Advertisement

;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.